31 May 2022
QuidelOrtho Corporation (San Diego, CA, USA) has announced the completion of the transaction combining Quidel Corporation (San Diego, CA, USA) and Ortho Clinical Diagnostics (Raritan, NJ, USA), creating QuidelOrtho, a leading in vitro diagnostics company.
Read More
24 Aug 2021
Ortho Clinical Diagnostics (Raritan, NJ, EUA) firmó un acuerdo de distribución con Thermo Fisher Scientific Inc. (Waltham, MA, EUA) para proporcionar y respaldar los controles de calidad MAS y el software de garantía de calidad LabLink xL a través de las soluciones VITROS QC de Ortho para los clientes del sistema VITROS todo el mundo.
Read More
08 Jul 2021
Ortho Clinical Diagnostics (Raritan, NJ, USA) has entered into a distribution agreement with Thermo Fisher Scientific Inc. (Waltham, MA, USA) to provide and support MAS Quality Controls and LabLink xL Quality Assurance Software through Ortho's VITROS QC Solutions to VITROS System customers worldwide.
Read More
28 May 2019
Ortho Clinical Diagnostics (Raritan, NJ, EUA) patrocinó un taller educativo sobre los ensayos de troponina de alta sensibilidad y presentó cinco pósteres científicos en EuroMedLab 2019, durante el 23º Congreso Europeo de Química Clínica y Medicina de Laboratorio IFCC-EFLM, que se realizó del 19 al 23 de mayo de 2019 en el CCIB -Centro de Convenciones Internacional de Barcelona. Ortho también mostró sus nuevas láminas de productos químicos VITROS, la Celda VITROS, una solución de automatización compacta que permite que dos instrumentos VITROS XT 7600 (lanzados en 2018) funcionen como una solución perfecta, y el Sistema Integrado VITROS XT 7600 en su stand durante el Congreso.
Read More
20 May 2019
Ortho Clinical Diagnostics sponsored an educational workshop on high-sensitivity troponin assays and presented five scientific posters at EuroMedLab 2019, the 23rd IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, which took place from May 19-23, 2019, at the CCIB - Centre Convencions Internacional in Barcelona.
Read More
17 Oct 2017
Ortho Clinical Diagnostics and EKF Diagnostics have entered into an agreement that allows Ortho customers to access the Beta-Hydroxybutyrate (BHB) assay, an important marker used in conjunction with clinical findings and other lab tests for the diagnosis and management of ketoacidosis and its main causative factor, diabetic ketoacidosis (DKA). The fully automated assay is now available for use on Ortho's VITROS 4600 chemistry system and the VITROS 5600 integrated system.
Read More